lansoprazole has been researched along with Sarcoma, Epithelioid in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuyaerts, S | 1 |
| Van Nuffel, AMT | 1 |
| Naert, E | 1 |
| Van Dam, PA | 1 |
| Vuylsteke, P | 1 |
| De Caluwé, A | 1 |
| Aspeslagh, S | 1 |
| Dirix, P | 1 |
| Lippens, L | 1 |
| De Jaeghere, E | 1 |
| Amant, F | 1 |
| Vandecasteele, K | 1 |
| Denys, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)[NCT03192059] | Phase 2 | 43 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lansoprazole and Sarcoma, Epithelioid
| Article | Year |
|---|---|
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aspirin; Chemoradiotherapy; Curcumin; Cycl | 2019 |